$SGHT

HAYDEN JEREMY B. sold $70K of SGHT

HAYDEN JEREMY B. (Chief Legal Officer) sold 12,733 shares of Sight Sciences, Inc. (SGHT) at $5.51 on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · HAYDEN JEREMY B.
Published Jul 6, 2026, 11:36 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 11:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SGHT
Neutral
medium confidence
Mentioned
$SGHT
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SGHTNeutralLow
01

Why it matters

The disclosed sale is an open-market transaction by the Chief Legal Officer and is explicitly under a pre-arranged Rule 10b5-1 plan, which typically reduces the signal of new negative information.

02

Market read

Traders may monitor insider activity for sentiment, but this specific disclosure lacks any fundamental catalyst.

03

What to watch

The article provides no context on total insider holdings changes beyond post-transaction shares, nor any link to earnings, guidance, or corporate events.

Relevance 2/10Novelty 3/10Timing: Filed same day as the sale (2026-07-06), but no new company event beyond the transaction.

Background

The article is a primary-source SEC Form 4 insider transaction for Sight Sciences, Inc. (SGHT).

Company-level read

Ticker impact

$SGHTNeutralMedium confidence
Context

Sight Sciences disclosed a Form 4 showing Chief Legal Officer Hayden sold 12,733 shares at $5.5080 on 2026-07-06 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment/flow optics.

Evidence & confidence

The filing is an open-market sale by an officer, explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying operational, financial, or regulatory catalyst in the text.

Market effects

No sector read-through provided; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a lack of near-term conviction.

Key entities

  • Sight Sciences, Inc.

    Subject of the Form 4 insider transaction; officer sale disclosed on 2026-07-06.

  • HAYDEN JEREMY B.

    Chief Legal Officer who sold 12,733 shares at $5.5080/share under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SGHTHighAI 8/10

FDA Broadens ‘Indications for Use’ for Sight Sciences’ TearCare System

Sight Sciences (SGHT) announced FDA expanded the TearCare System's use to improve meibomian gland function in adults with evaporative dry eye disease due to MGD. This makes TearCare the first treatment indicated for this purpose, according to the company. The update also includes optional debridement, enhancing its approach to treating the condition. SGHT reported Q2 2026 revenue growth and updated its full-year guidance earlier this month.

$SGHTMedAI 8/10

Sight Sciences, Inc.: TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

Sight Sciences (SGHT) announced FDA approval for its TearCare System to improve meibomian gland function in patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). This makes TearCare the first and only treatment indicated for this purpose, expanding its market potential. The company's CEO and a medical expert highlighted the significance of this milestone in dry eye disease treatment.

$SGHTHighAI 8/10

TearCare is the first and only treatment indicated to improve gland function in dry-eye patients

Sight Sciences (SGHT) announced that the FDA expanded the TearCare System's indication to include improving meibomian gland function in adults with evaporative dry eye disease due to MGD. This makes TearCare the first and only treatment with this indication, effective August 18, 2026. The update also incorporates optional debridement into the system's treatment approach.

$SGHTMedAI 8/10

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

Sight Sciences (SGHT) announced FDA expanded approval for its TearCare System, now the only treatment indicated to improve meibomian gland function in patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). The update includes optional debridement, enhancing its comprehensive approach to treating MGD. According to the company, this milestone reflects its commitment to advancing dry eye disease treatment.

$SGHTMedAI 8/10

Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences (SGHT) reported Q2 2026 revenue of $23.4M, up 20% y/y, driven by Interventional Glaucoma ($20.7M) and Interventional Dry Eye ($2.7M). Gross margin rose to 91% from 85%. Net loss was $4.4M. FY2026 revenue guidance raised to $88M-$92M; adjusted opex guidance lowered to $92M-$94M. Alcon patent appeal remains pending.